Literature DB >> 29351936

Intravitreal bevacizumab for postviral fever retinitis: a novel approach for early resolution of macular oedema.

Rohan Chawla1, Dheepak M Sundar1, Prasad Gupta1, Kanhaiya Mittal1.   

Abstract

Severe macular oedema causing marked loss of vision is seen in cases of retinitis developing postviral fever. The use of antivascular endothelial growth factor agents for macular oedema and submacular fluid secondary to viral retinitis has not been studied or well established in the past. We report a case series of two patients of postviral retinitis with severe macular oedema resistant to steroid therapy, treated with intravitreal bevacizumab. The patients showed significant symptomatic improvement in the visual acuity. The retinitis lesions resolved slowly and macular oedema regressed. Bevacizumab appears to be a safe and useful agent to manage macular oedema subsequent to postviral retinitis. An early resolution of macular oedema helps in the preservation of visual acuity which left untreated can cause severe visual loss. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  eye; macula; retina; therapeutic indications

Mesh:

Substances:

Year:  2018        PMID: 29351936      PMCID: PMC5775810          DOI: 10.1136/bcr-2017-222410

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  2 in total

1.  Anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis.

Authors:  Ankush A Kawali; Ashwin Mohan; Ruchir Mehta; Padmamalini Mahendradas; Sanjay Srinivasan; Bhujang Shetty
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

2.  Clinical features, optical coherence tomography findings and treatment outcomes of post-fever retinitis.

Authors:  Dheepak Sundar M; Rohan Chawla; Akshaya Balaji; Itika Garg; Reshmi Kalathil; Nasiq Hasan; S J Vikas; Atul Kumar
Journal:  Ther Adv Ophthalmol       Date:  2020-12-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.